Educational videos featured by Pituitary World News
This is my conversation with Dr. Ken Ho, Professor at St. Vincent’s Hospital, Sydney and Garvan Institute of Medical Research, Sydney, Australia, on why a single word could change how pituitary patients are treated, and why leading endocrinologists are asking the WHO (World Health Organization) to reconsider.
I sat down with Dr. Leena Shahla, medical director of the Duke Pituitary Center to talk about the latest developments from ENDO 2026. Many in of our readers will remember her from an earlier Pituitary World News Podcast conversation with our co-founder, Dr. Lewis Blevins, on the tricky business of distinguishing pseudo-Cushing’s from the real thing. This time, the focus was the fast-moving world of acromegaly therapy.
For those of us living with pituitary and adrenal disease, the genetic and molecular information in tumors can help clarify an uncertain diagnosis, suggest whether an existing therapy is likely to work, and increasingly, point toward treatments designed specifically for the biology involved.
We ran into Sonnie Kim, Camurus’ head of Medical Affairs, at this year’s ENDO2026 conference in Chicago and asked her about the latest on CAM2029, the long-acting octreotide subcutaneous depot delivered by a pre-filled pen, built on the company’s FluidCrystal technology. The product is approved in Europe under the brand name Oczyesa and is still awaiting US approval.
From our ENDO 2026 series, PWN contributor and Assistant professor of Medicine at UCSF, Dr. Francesca Galbiati, talks with Dr. Woun Seo, Senior Director of Medical Affairs at Eton Pharmaceuticals about the liquid oral formulation of desmopressin recently launched under the trade name Desmoda by Eton Pharmaceuticals.
In this episode, Isabelle Petit, senior manager at Debiopharm, a leading development company headquartered in Lausanne, Switzerland, discusses the latest data from a clinical trial of a three-month formulation for acromegaly treatment, highlighting its impact on patient quality of life and treatment satisfaction.
In this episode from our ENDO 2026 series , Dr. Lewis Blevins talks with Dr. Francesca Galbiati about her research on oxytocin deficiency, exploring provocative tests, recent findings, and future directions in endocrinology. Building on work she began during her fellowship at Massachusetts General Hospital, Dr. Galbiati and her colleagues tested whether cosyntropin, a synthetic hormone already used routinely to check adrenal function, might also “provoke” the body into releasing oxytocin.
In this conversation recorded at ENDO 2026 in Chicago a few weeks ago, we sit down with Dr. Kevin Yuen, medical director of the Barrow Pituitary Center in Phoenix, Arizona, to discuss one of the most challenging periods in pituitary care: the transition from pediatric to adult services. Dr. Yuen explains why these years are so vulnerable.
At ENDO 2026, Dr. Richard Auchus of the University of Michigan shares his perspectives on the connection between type 2 diabetes and hard-to-control hypertension and high cortisol in Corcept Therapeutics’ landmark studies. The interview covers two related studies investigating how often “common” diseases—difficult-to-control diabetes and hypertension are actually being driven by undiagnosed adrenal dysfunction, particularly mild, clinically significant cortisol excess from adrenal adenomas.
In the latest episode of the Pituitary World News podcast, Jorge D. Faccinetti sits down with Dr. Markus Johnsson, Senior VP of R&D at Camurus, to explore the fascinating world of FluidCrystal® technology. This innovative approach promises to revolutionize the way we think about drug delivery, providing long-lasting solutions for chronic diseases particularly for people with acromegaly.